Our History

//Our History
Our History2019-01-17T14:51:09+01:00

LEADERSHIP IN LATERAL FLOW TECHNOLOGY SINCE 2003

Mologic was founded in 2003 by Paul and Mark Davis and now employs 65 people in the UK and USA. Here are some of the milestones along the way.

In the beginning

2003

Mologic started with a laboratory in Bedford, UK delivering high-value contract research and innovation to local clients

Investment for growth

2005

Mologic secured private investment which accelerated the development of our core technology and IP portfolio.

Attracting major clients

2006

By now we had established a strong track record and attracted clients including the NHS, Inverness Medical, 3M and Church and Dwight.

Acquired by Alere

2009

Mologic was acquired by Alere (formerly Inverness Medical) and became a dedicated R&D group with long-term targets.

Growing capabilities

2010

We established the respiratory disease business unit and sepsis programme. We acquired Ovine antibody capability to support small molecule reagent and high-performance antibody development.

Wound Chek goes live

2012

Our chronic wound care diagnostic product reached the market, launched as Wound Chek by Systagenix.

Independent again

2014

Mologic became an independent company again after an investor buy-in and management buy-back. We retained all the Mologic technology, personnel, facilities, capability, intellectual property and a deep product pipeline.

A dynamic product pipeline

2015

We secured investment for product development and the delivery of an extensive product pipeline. Mologic became ISO 13485 and CMDCAS certified (including self-testing).

Transformational investment

2016

We established the Centre for Advanced Rapid Diagnostics (CARD) with the backing of a grant from the Bill & Melinda Gates Foundation. The centre focuses on the development of a transformational, low-cost, next-generation rapid point-of-care platform that doesn’t require a reader.

Mologic goes to Market

2017

The first products from the Mologic portfolio achieved the CE mark and were launched commercially: BVProⓇ for women’s health and PERiPLEXⓇ for peritoneal dialysis.

Expansion into the USA

2018

Mologic secured investment to expand into North America and established a US headquarters near Boston, MA.

Discover The Future With Mologic

Contact Us